A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)

被引：1

作者：

Hollebecque, Antoine ^{[1
]}

Lopez, Juanita ^{[2
]}

Piha-Paul, Sarina ^{[3
]}

Dowlati, Afshin ^{[4
]}

Patnaik, Amita ^{[5
]}

Galvao, Vladimir ^{[6
]}

Buckorny, Bruno ^{[7
]}

Sehgal, Kartik ^{[8
]}

Kingsley, Edwin ^{[9
]}

Sanborn, Rachel ^{[10
]}

Peters, Solange ^{[11
]}

Sun, Yan ^{[12
]}

Patilea-Vrana, Gabriela ^{[12
]}

Nazarenko, Natalya ^{[12
]}

Calvo, Emiliano ^{[13
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Royal Marsden Hosp Surrey, London, England

[3] Univ Texas Houston, Houston, TX USA

[4] Case Western Reserve Univ, Cleveland, OH USA

[5] START San Antonio, San Antonio, TX USA

[6] Vall dHebron Inst Oncol, Barcelona, Spain

[7] Beth Israel Deaconess Med Ctr, Boston, MA USA

[8] Dana Farber Canc Inst, Boston, MA USA

[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[10] Earle A Chiles Res Inst, Portland, OR USA

[11] CHU Vaudois, Lausanne, Switzerland

[12] Seagen Inc, Bothell, WA USA

[13] START Madrid CIOCC, Madrid, Spain

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0731

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

731

引用

页码：A763 / A763

页数：1

共 50 条

[1] SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)
Hollebecque, Antoine
Lopez, Juanita Suzanne
Piha-Paul, Sarina A.
Dowlati, Afshin
Patnaik, Amita
Galvao, Vladimir
Bockorny, Bruno
Sehgal, Kartik
Kingsley, Ed
Sanborn, Rachel E.
Perez, Cesar Augusto
Peters, Solange
Yan, Mingjin
Nazarenko, Natalya N.
Calvo, Emiliano
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).
Patnaik, Amita
Calvo, Emiliano
Piha-Paul, Sarina Anne Anne
Hollebecque, Antoine
Galvao, Vladimir
Lopez, Juanita Suzanne
Braiteh, Fadi S.
Sanborn, Rachel E.
Zhou, Peigen
Nazarenko, Natalya N.
Dowlati, Afshin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] A first-in-human trial of the integrin beta-6-targeted antibody-drug conjugate, SGN-B6A, in patients with advanced solid tumors
Calvo, E.
Hollebecque, A.
Dowlati, A.
Piha-Paul, S. A.
Galvao, V.
Lopez, J.
Sehgal, K.
Bockorny, B.
Braiteh, F.
Peters, S.
Sanborn, R. E.
Zhou, P.
Nazarenko, N.
Patnaik, A.
ANNALS OF ONCOLOGY, 2021, 32 : S613 - S613
[4] Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
Wang, Jie
Wu, Lin
Song, Zhengbo
Li, Xingya
Liu, Caigang
Liu, Tianshu
Wu, Yiwen
Zhang, Ze
Wang, Shuni
CANCER RESEARCH, 2023, 83 (08)
[6] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana, Sreenivasa R.
Choudhury, Noura J.
Dowlati, Afshin
Chiang, Anne C.
Garmezy, Benjamin
Kim, Joo-Hang
Byers, Lauren Averett
Ahn, Myung-Ju
Kim, Tae Min
Kim, Young-Chul
Han, Ji-Youn
Bar, Jair
Zha, Jiuhong
Henner, William
Robinson, Randy
Kohlhapp, Fred
Hingorani, Pooja
Papadopoulos, Kyriakos P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Konecny, G. E.
Hendrickson, A. E. Wahner
Winterhoff, B.
Machado, A.
Chander, C.
Davenport, S.
Bilic, S.
Miller, L. L.
Chung, A.
Press, M. F.
Letrent, S.
Slamon, D.
ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
[8] FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER
Konecny, Gottfried
Hendrickson, Andrea Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael
Letrent, Stephen
Slamon, Dennis
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A67 - A67
[9] Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors
Coward, Jim
Kichenadasse, Ganessan
Park, John J.
Parakh, Sagun
Richardson, Gary Edward
Voskoboynik, Mark
Powderly, John D., II
Song, Zhengbo
Liu, Shutong
Huang, Yaling
Liu, Shu-Hui
Meng, Xun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1-23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
Konecny, Gottfried
Hendrickson, Andrea Wahner
Winterhoff, Boris
Kung, Adrine
Miller, Lei-Lani
Press, Michael
Qazi, Ibrahim
Scholler, Nathalie
Dokainish, Hatem
Letrent, Stephen
Slamon, Dennis
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A56 - A56

← 1 2 3 4 5 →